Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H14N4O5S |
Molecular Weight | 314.318 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC(=O)N1[C@@H](C([O-])=O)[C@](C)(CN3C=C[N+](C)=N3)S2(=O)=O
InChI
InChIKey=HFZITXBUTWITPT-YWVKMMECSA-N
InChI=1S/C11H14N4O5S/c1-11(6-14-4-3-13(2)12-14)9(10(17)18)15-7(16)5-8(15)21(11,19)20/h3-4,8-9H,5-6H2,1-2H3/t8-,9+,11+/m1/s1
Molecular Formula | C11H14N4O5S |
Molecular Weight | 314.318 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:48:59 GMT 2023
by
admin
on
Sat Dec 16 11:48:59 GMT 2023
|
Record UNII |
80VUN7L00C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C171696
Created by
admin on Sat Dec 16 11:48:59 GMT 2023 , Edited by admin on Sat Dec 16 11:48:59 GMT 2023
|
PRIMARY | |||
|
23653540
Created by
admin on Sat Dec 16 11:48:59 GMT 2023 , Edited by admin on Sat Dec 16 11:48:59 GMT 2023
|
PRIMARY | |||
|
300000010200
Created by
admin on Sat Dec 16 11:48:59 GMT 2023 , Edited by admin on Sat Dec 16 11:48:59 GMT 2023
|
PRIMARY | |||
|
80VUN7L00C
Created by
admin on Sat Dec 16 11:48:59 GMT 2023 , Edited by admin on Sat Dec 16 11:48:59 GMT 2023
|
PRIMARY | |||
|
1001404-83-6
Created by
admin on Sat Dec 16 11:48:59 GMT 2023 , Edited by admin on Sat Dec 16 11:48:59 GMT 2023
|
PRIMARY | |||
|
10913
Created by
admin on Sat Dec 16 11:48:59 GMT 2023 , Edited by admin on Sat Dec 16 11:48:59 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
We evaluated the in vitro potency of cefepime combined with AAI101, a novel extended-spectrum .BETA.-lactamase inhibitor, against a population of clinical Escherichia coli and Klebsiella pneumoniae collected from USA hospitals. Of the 223 cefepime non-susceptible isolates, 95% were ceftazidime non-susceptible, 49% ertapenem non-susceptible, 57% piperacillin/tazobactam non-susceptible, 90% were multidrug-resistant (resistant to 3 drug classes), 22% produced carbapenemases, and 67% produced ESBLs. Addition of AAI101 restored the activity of cefepime such that the MIC50 was reduced from >64 mg/L for cefepime to 0.13 mg/L for cefepime/AAI101, supporting its continued development treatment for infections caused by these organisms.
|